{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:59:14Z","timestamp":1770350354353,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006250","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T00:00:00Z","timestamp":1514246400000}}],"reference-count":98,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006250.pub2","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T14:46:08Z","timestamp":1514299568000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bisphosphonates for advanced prostate cancer"],"prefix":"10.1002","volume":"2017","author":[{"given":"Sascha","family":"Macherey","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[{"name":"Martin-Luther-University Halle-Wittenberg; Department of Internal Medicine IV; Hematology\/Oncology; Halle Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[{"name":"University of Heidelberg; Department of Medicine V; Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok Keung","family":"Yuen","sequence":"additional","affiliation":[{"name":"Queen Mary Hospital; Department of Clinical Oncology; 102 Pok Fu Lam Road 1\/F Professorial Block Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"University Hospital Cologne; Department of Urology; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,26]]},"reference":[{"key":"10.1002\/14651858.CD006250.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1200\/jco.2006.24.18_suppl.4638","article-title":"Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial","author":"Abetz","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD006250.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"14544","DOI":"10.1200\/jco.2006.24.18_suppl.14544","article-title":"Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status","volume":"24","author":"Barghout","year":"2006","journal-title":"Journal of Clinical Oncology - Supplement"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006250.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostate cancer","volume":"24","author":"Elomaa","year":"1992","journal-title":"International Journal of Urology and Nephrology"},{"issue":"17","key":"10.1002\/14651858.CD006250.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantron\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/01.ju.0000147013.09157.8e","article-title":"A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases","volume":"173","author":"Figg","year":"2005","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD006250.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clgc.2013.07.002","article-title":"Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event","volume":"12","author":"Hahn","year":"2014","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/jco.2011.29.15_suppl.4594","article-title":"Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer","volume":"29","author":"Sharma","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"e15000","DOI":"10.1200\/jco.2010.28.15_suppl.e15000","article-title":"A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT)","volume":"28","author":"Sweeney","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006250.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0959-8049(05)80417-4","article-title":"Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group","volume":"29A","author":"Kylmala","year":"1993","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant i.v. and oral clodronate in the relief of bone pain: a double-blind placebo-controlled study in patients with metastatic prostate cancer","volume":"76","author":"Kylmala","year":"1997","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ejca.2012.05.014","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)","volume":"48","author":"Meulenbeld","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s11255-014-0824-9","article-title":"Docetaxel with or without zoledronic acid for castration-resistant prostate cancer","volume":"46","author":"Pan","year":"2014","journal-title":"International Urology and Nephrology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncology"},{"issue":"17","key":"10.1002\/14651858.CD006250.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomised trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO5 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","article-title":"Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer","volume":"76","author":"Saad","year":"2010","journal-title":"Urology"},{"issue":"19","key":"10.1002\/14651858.CD006250.pub2-BIB0018|cit17","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","article-title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","volume":"17","author":"Weinfurt","year":"2006","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.1002\/14651858.CD006250.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostatic cancer","volume":"21","author":"Small","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study","volume":"141","author":"Smith","year":"1989","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0022|cit22","first-page":"4717","article-title":"The analgesic efficacy of clodronate compared with placebo inpatients with painful bone metastases from prostatic cancer","volume":"17","author":"Strang","year":"1997","journal-title":"Anticancer Research"},{"issue":"53","key":"10.1002\/14651858.CD006250.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20530","article-title":"TRAPEZE: A randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer","volume":"20","author":"James","year":"2016","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e16108","DOI":"10.1200\/jco.2015.33.15_suppl.e16108","article-title":"Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE","volume":"33","author":"James","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"LBA5000","DOI":"10.1200\/jco.2013.31.18_suppl.lba5000","article-title":"Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)","volume":"31","author":"James","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006250.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","article-title":"Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/jco.2010.28.15_suppl.4677","article-title":"Initial feasibility and safety results from a phase II\/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) {+\/-} strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747","volume":"28","author":"Porfiri","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0028|cit28","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid\/androgen blockade trial on prostate cancer) study","volume":"33","author":"Ueno","year":"2013","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"Kamba","year":"2017","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/jco.2015.33.7_suppl.150","article-title":"A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naive prostate cancer patients with bone metastases: Results of ZAPCA study","volume":"33","author":"Kamba","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S0022-5347(17)47663-4","article-title":"Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton","volume":"134","author":"Adami","year":"1985","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-642-83668-8_6","article-title":"Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma","volume":"116","author":"Adami","year":"1989","journal-title":"Recent Results in Cancer Research"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0033|cit33","unstructured":"BO18039 Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in patients with malignant and painful bone disease www.clinicaltrialsregister.eu\/ctr-search\/search?query=2004-001854-10"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/jco.2015.33.15_suppl.9501","article-title":"CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer","volume":"33","author":"Himelstein","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0090-4295(88)90410-4","article-title":"Treatment of painful prostatic bone metastases with oral etidronate disodium","volume":"32","author":"Carey","year":"1988","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD006250.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/bjc.1991.97","article-title":"Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study","volume":"63","author":"Clarke","year":"1991","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.1995.tb07715.x","article-title":"Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer","volume":"76","author":"Cresswell","year":"1995","journal-title":"British Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006250.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00000421-199710000-00007","article-title":"Skeletal response to clodronate in prostate cancer with bone metastases","volume":"20","author":"Fernandez-Conde","year":"1997","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"509-15; discuss","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"18","key":"10.1002\/14651858.CD006250.pub2-BIB0041|cit41","first-page":"951","article-title":"A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer [abstract no. LBA4507]","volume":"28","author":"Fizazi","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006250.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","article-title":"The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer","volume":"165","author":"Heidenreich","year":"2001","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD006250.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease","volume":"12","author":"Jagdev","year":"2001","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006250.pub2-BIB0046|cit46","first-page":"316","article-title":"The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer","volume":"83","author":"Kylmala","year":"1994","journal-title":"Annales Chirurgiae et Gynaecologiae"},{"issue":"8 Pt 1","key":"10.1002\/14651858.CD006250.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/clinchem\/44.8.1621","article-title":"Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by location of pain","volume":"44","author":"Magnusson","year":"1998","journal-title":"Clinical Chemistry"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1200\/jco.2009.27.15_suppl.5161","article-title":"MER-101-03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients","volume":"27","author":"McHugh","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S8756-3282(97)00289-5","article-title":"Effects of the bisphosphonate olpadronate in patients with carcinoma of prostate metastatic to the skeleton","volume":"22","author":"Pelger","year":"1998","journal-title":"Bone"},{"issue":"10024","key":"10.1002\/14651858.CD006250.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2015.33.15_suppl.5001","article-title":"Docetaxel and\/or zoledronic acid for hormone-naive prostate cancer: first overall survival results from STAMPEDE (NCT00268476)","volume":"33","author":"James","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0959-8049(94)90287-9","article-title":"The effect of clodronate on bone in metastatic prostate cancer: histomorphonmetric report of a double-blind randomised placebo-controlled study","volume":"30","author":"Taube","year":"1994","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD006250.pub2-BIB0053|cit53","first-page":"63","article-title":"Clodronate in the palliative therapy of bone-metastasized prostate carcinoma","volume":"31","author":"Vorreuther","year":"1992","journal-title":"Urologe A"},{"issue":"(5 Pt 2)","key":"10.1002\/14651858.CD006250.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1464-410X.1993.tb16269.x","article-title":"Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostate carcinoma. A pilot study on clodronate","volume":"72","author":"Vorreuther","year":"1993","journal-title":"British Journal of Urology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12032-013-0657-x","article-title":"Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases","volume":"30","author":"Wang","year":"2013","journal-title":"Medical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006250.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clon.2017.01.007","article-title":"Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline","volume":"29","author":"Alibhai","year":"2017","journal-title":"Clinical oncology (Royal College of Radiologists (Great Britain))"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0057|cit57","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-69870-8","volume-title":"Bisphosphonates in Medical Practice - Actions, Side effects, Indications, Strategies","author":"Bartl","year":"2007"},{"issue":"6","key":"10.1002\/14651858.CD006250.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00132-008-1280-y","article-title":"Use of bisphosphonates in orthopedic surgery","volume":"37","author":"Bartl","year":"2008","journal-title":"Der Orthop\u00e4de"},{"issue":"5","key":"10.1002\/14651858.CD006250.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Human Pathology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD006250.pub2-BIB0060|cit60","first-page":"866","article-title":"Bone cancer pain","volume":"97","author":"Clohisy","year":"2002","journal-title":"Cancer"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD006250.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"14","key":"10.1002\/14651858.CD006250.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD006250.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006250.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.juro.2013.05.005","article-title":"Castration-resistant prostate cancer: AUA guideline","volume":"190","author":"Cookson","year":"2013","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0065|cit65","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00002281-200007000-00017","article-title":"Treatment of bone diseases with bisphosphonates, excluding osteoporosis","volume":"12","author":"Devogelaer","year":"2000","journal-title":"Current Opinion in Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006250.pub2-BIB0067|cit67","first-page":"11","article-title":"Targeting bone metastases in metastatic castration-resistant prostate cancer","volume":"10","author":"El-Amm","year":"2016","journal-title":"Clinical Medicine Insight: Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0068|cit68","unstructured":"Ferlay J Soerjomataram I Ervik M Dikshit R Eser S Mathers C Cancer incidence and mortality worldwide: IARC CancerBase No. 11, 2013 globocan.iarc.fr"},{"issue":"9","key":"10.1002\/14651858.CD006250.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006250.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","article-title":"Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer","volume":"68","author":"Fizazi","year":"2015","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD006250.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eururo.2013.05.015","article-title":"Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappaB ligand inhibitors in patients with advanced prostate cancer","volume":"65","author":"Gartrell","year":"2014","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD006250.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","article-title":"Metastatic prostate cancer and the bone: significance and therapeutic options","volume":"68","author":"Gartrell","year":"2015","journal-title":"European Urology"},{"issue":"11","key":"10.1002\/14651858.CD006250.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"Journal of the American Dental Association"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0074|cit74","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0075|cit75","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0076|cit76","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"vi106","DOI":"10.1093\/annonc\/mdt208","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24 Suppl 6","author":"Horwich","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0078|cit78","unstructured":"Howlader N Noone AM Krapcho M Garshell J Miller D Altekruse SF SEER cancer statistics review, 1975-2012, based on November 2014 SEER data submission, posted to the SEER website, April 2015 seer.cancer.gov\/csr\/1975_2012\/"},{"issue":"2","key":"10.1002\/14651858.CD006250.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00520-013-2017-y","article-title":"Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies","volume":"22","author":"Lee","year":"2014","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0080|cit80","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"46","key":"10.1002\/14651858.CD006250.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"e2014","DOI":"10.1097\/MD.0000000000002014","article-title":"Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer: a meta-analysis","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1002\/14651858.CD006250.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006250.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD006250.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","article-title":"Prostate cancer, version 1.2016","volume":"14","author":"Mohler","year":"2016","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"5","key":"10.1002\/14651858.CD006250.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","article-title":"Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk","volume":"102","author":"Newcomb","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"24","key":"10.1002\/14651858.CD006250.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00002281-200307000-00014","article-title":"Bisphosphonates: new indications and methods of administration","volume":"15","author":"Reid","year":"2003","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0088|cit88","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"1","key":"10.1002\/14651858.CD006250.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"Journal of Cellular Biochemistry"},{"issue":"5","key":"10.1002\/14651858.CD006250.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1191\/0269216304pm914ra","article-title":"Systematic review of bisphosphonates for hypercalcaemia of malignancy","volume":"18","author":"Saunders","year":"2004","journal-title":"Palliative Medicine"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0091|cit91","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0092|cit92","unstructured":"Sterne JAC Egger M Moher D Chapter 10: addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD006250.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2012.42.9530","article-title":"Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis","volume":"31","author":"Thosani","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.02.002","article-title":"Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer","volume":"44","author":"Vignani","year":"2016","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD006250.pub2-BIB0096|cit96","volume-title":"Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 4.0","author":"Wirth","year":"2016"},{"issue":"2","key":"10.1002\/14651858.CD006250.pub2-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003474.pub3","article-title":"Bisphosphonates and other bone agents for breast cancer","author":"Wong","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD006250.pub2-BIB0098|cit98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006250","article-title":"Bisphosphonates for advanced prostate cancer","author":"Yuen","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006250.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T02:48:47Z","timestamp":1680058127000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006250.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,26]]},"references-count":98,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006250.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,26]]}}}